Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients

X
Trial Profile

Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients

Status: Not stated
Phase of Trial: Phase II/III

Latest Information Update: 19 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary) ; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Folinic acid; Hydrocortisone; Methotrexate; Methotrexate; Methylprednisolone; Prednisolone; Prednisone; Vincristine
  • Indications B-cell leukaemia; B-cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Acronyms Inter-B-NHL ritux 2010
  • Most Recent Events

    • 16 Feb 2024 This study has been completed in Poland, according to European Clinical Trials Database record.
    • 23 Oct 2023 This study has been completed in Netherland, according to European Clinical Trials Database record.
    • 27 Sep 2021 Primary endpoint (Event free survival) has not been met, according to Results published in the Journal of Clinical Oncology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top